Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK8 | P45983 | 15/20 | 0.84 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | DPP4 | P27487 | 1/20 | 0.53 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.53 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4713111 | 0.91 | MAPK8 (1.00) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4713882 | 0.89 | MAPK8 (0.68) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4711435 | 0.88 | MAPK8 (0.66) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4709122 | 0.82 | MAPK8 (0.61) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4712252 | 0.82 | MAPK8 (0.78) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4709411 | 0.82 | MAPK8 (0.83) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4712360 | 0.81 | MAPK8 (0.81) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4713124 | 0.81 | MAPK8 (0.81) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4712561 | 0.80 | MAPK8 (1.00) | MAPK8MAPK9MAPK10 | |
| SCHEMBL4709742 | 0.80 | MAPK8 (1.00) | MAPK8MAPK9MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7402595-B2 | Enzyme inhibitors with isoquinolinone structures | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-07-22 | — | — | US | disclosed |
| US-20050148624-A1 | Jnk inhibitor | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1484320-A1 | JNK INHIBITOR | Takeda Chemical Industries, Ltd. (JP) | 2004-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050148624-A1 | Jnk inhibitor | MAPK3, MAPKAPK3, MAPK1 | MAPK8 5/4885KCNA5 2448/4885KCNH2 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.